Abbonarsi

Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies - 20/04/22

Doi : 10.1016/j.biopha.2022.112898 
Md. Mominur Rahman a, Md. Rezaul Islam a, Sheikh Shohag b, Md. Tanjimul Ahasan a, Nadia Sarkar a, Hosneara Khan a, Alexandru Madalin Hasan c, , Simona Cavalu c, Abdur Rauf d,
a Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh 
b Department of Biochemistry and Molecular Biology, Faculty of Life Science, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh 
c Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, Oradea 410087, Romania 
d Department of Chemistry, University of Swabi, Anbar, Swabi, KPK, Pakistan 

Corresponding authors.

Abstract

Cancer is the world's second-leading cause of death, and the involvement of microbes in a range of diseases, including cancer, is well established. The gut microbiota is known to play an important role in the host's health and physiology. The gut microbiota and its metabolites may activate immunological and cellular pathways that kill invading pathogens and initiate a cancer-fighting immune response. Cancer is a multiplex illness, characterized by the persistence of several genetic and physiological anomalies in malignant tissue, complicating disease therapy and control. Humans have coevolved with a complex bacterial, fungal, and viral microbiome over millions of years. Specific long-known epidemiological links between certain bacteria and cancer have recently been grasped at the molecular level. Similarly, advances in next-generation sequencing technology have enabled detailed research of microbiomes, such as the human gut microbiome, allowing for the finding of taxonomic and metabolomic linkages between the microbiome and cancer. These investigations have found causative pathways for both microorganisms within tumors and bacteria in various host habitats far from tumors using direct and immunological procedures. Anticancer diagnostic and therapeutic solutions could be developed using this review to tackle the threat of anti-cancer medication resistance as well through the wide-ranging involvement of the microbiota in regulating host metabolic and immunological homeostasis. We reviewed the significance of gut microbiota in cancer initiation as well as cancer prevention. We look at certain microorganisms that may play a role in the development of cancer. Several bacteria with probiotic qualities may be employed as bio-therapeutic agents to re-establish the microbial population and trigger a strong immune response to remove malignancies, and further study into this should be conducted.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Microbiome plays a key role in human health and disease, and gut microbiome affects immunity both locally and systemically.
The gut microbiome has emerged as a new prognostic biomarker and a potential therapeutic target to enhance the efficacy of immunotherapy.
Role in carcinogenesis for the treatment of microbiome in cancer.
Care needs to be given to protecting the microbiome, both by clinicians and patients.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Cancer, Microbiome, Bacteria, Therapeutic agent, Immune response


Mappa


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 149

Articolo 112898- maggio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Endoplasmic reticulum stress in airway hyperresponsiveness
  • Qirui Duan, Ying Zhou, Dong Yang
| Articolo seguente Articolo seguente
  • Hesperidin and hesperetin against heavy metal toxicity: Insight on the molecular mechanism of mitigation
  • Ademola C. Famurewa, Kaviyarasi Renu, Mohamed Ahmed Eladl, Rituraj Chakraborty, Haritha Myakala, Mohamed El-Sherbiny, Dalia Mahmoud Abdelmonem Elsherbini, Balachandar Vellingiri, Harishkumar Madhyastha, Uddesh Ramesh Wanjari, Anirban Goutam Mukherjee, Abilash Valsala Gopalakrishnan

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.